Objective: To test the hypothesis that once-daily treatment with fluticasone propionate is as effective as twice-daily treatment in children with well controlled asthma. Design: Multicentre ...
Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20%YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates ...
Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary ...
today announced preliminary unaudited XHANCE® (fluticasone propionate) net product revenue of $22.4 million for the three months ended December 31, 2024. “Our preliminary unaudited fourth ...
The Chippenham-based company has an asthma drug on the market called Flutiform (fluticasone propionate/ formoterol fumarate) which is sold by Mundipharma, a generic version of GlaxoSmithKline's ...
fluticasone propionate and short-acting beta agonist (SABA) albuterol sulfate. The drug – delivered using a proprietary Teva inhaler – could become the first ICS/SABA for both the adult and ...
MyChesCo on MSN2d
Optinose Reports $22.4 Million in Preliminary Q4 Revenue for XHANCEOptinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback